EU Lemtrada Decision Key to Genzyme CVR Holders

By Andrew Berens, MD Senior Healthcare Analyst, Bloomberg Industries

Sanofi’s multiple sclerosis (MS) drug Lemtrada may soon be recommended for European approval, where revenue is especially important to holders of Genzyme contingent value rights linked to the drug’s success.

Bloomberg BRIEF Newsletters